References
- Docteur E, Paris V, Moise P. Pharmaceutical pricing policies in a global market. Paris: Organisation for Economic Co-operation and Development; 2008
- Danzon PM, Epstein AJ. Effects of regulation on drug launch and pricing in interdependent markets. Adv Health Econ Health Serv Res 2012;23:35-71
- Robbins S. Pharmaceutical launch sequencing: time to rethink the approach (2013). www.innoperitus.com/website/images/%5Cinsights%5CLaunch_Sequencing_12aug2013.pdf [Accessed 26 February 2014]
- Bouvy J, Vogler S. Pricing and reimbursement policies: impacts on innovation. In: Priority medicines for Europe and the world—2013 update. Kaplan W, Wirtz V, Mantel Teuwisse A, Laing R, (Eds). World Health Organization; Geneva: 2013
- Chicoye A, Chhabra A. France: pharmaceuticals. In: ISPOR global health care systems road map. ISPOR (2009). www.ispor.org/htaroadmaps/France.asp#4 [Accessed 19 January 2014]
- Paris V, Belloni A. Value in pharmaceutical pricing. OECD Health Working Papers, No. 63. OECD Publishing (2013). http://dx.doi.org/10.1787/5k43jc9v6knx-en [Accessed 24 April 2014]
- Klemp M, Frønsdal KB, Facey K; HTAi Policy Forum. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care 2011;27(1):77-83
- Morel T, Arickx F, Befrits G, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis 2013;8:198
- National Institute for Health and Clinical Excellence. Incorporating health economics in guidelines and assessing resource impact. In: The guidelines manual. NICE, London (2007). www.nice.org.uk/niceMedia/pdf/GuidelinesManualChapter8.pdf [Accessed 24 February 2014]
- National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments.NICE, London (2009). www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf [Accessed 24 February 2014]
- Gesundheit Österreich. Preferred terms. http://whocc.goeg.at/Glossary/PreferredTerms/External%20price%20referencing [Accessed 29 April 2014]
- European Federation of Pharmaceutical Industries and Associations. Glossary of terms (2012). www.efpia.eu/uploads/documents/EFPIA-Annual-Review-2012-spreads.pdf [Accessed 19 January 2014]
- Toumi M, Rémuzat C, Vataire AL, Urbinati D. External reference pricing of medicinal products: simulation-based considerations for cross-country coordination (2014). European Union
- Gandjour A. Reference pricing and price negotiations for innovative new drugs: viable policies in the long term? Pharmacoeconomics 2013;31(1):11-14
- Kanavos P, Espin J, van der Aardweg S. Short- and long-term effects of value-based pricing vs. external price referencing. EMINET (2010). http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/valuebased_pharmapricing_012010_en.pdf [Last accessed 28 April 2014]
- Banerjee A, Pogge T, Hollis A. The health impact fund. Lancet 2010;375(9727):1693
- Gandjour A, Chernyak N. A new prize system for drug innovation. Health Policy 2011;102(2-3):170-7
- Danzon PM, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ 2013. [Epub ahead of print]
- Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(6):735-41
- Gandjour A. Presenting Germany’s drug pricing rule as a cost-per-QALY rule. Health Care Manag Sci 2012;15(2):103-7
- Kanavos P, Vandoros S, Irwin R, et al. Differences in costs of and access to pharmaceutical products in the EU. Directorate General for Internal Policies (2011). European Parliament, Brussels
- Leopold C, Mantel-Teeuwisse AK, Vogler S, et al. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 2013;112(3):209-16
- Houy N, Jelovac I. Drug launch timing and international reference pricing (January 1, 2013). GATE Groupe d’Analyse et de Théorie Économique Lyon-St Étienne Working Paper WP 1301. Available from: SSRN http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2207816. [Last accessed on 11 October 2014]